New progress in the treatment of diffuse midline glioma with H3K27M alteration

Zhi Yang; Liang Sun; Haibin Chen; Caixing Sun; Liang Xia

doi:10.1016/j.heliyon.2024.e24877

New progress in the treatment of diffuse midline glioma with H3K27M alteration

Heliyon. 2024 Jan 18;10(2):e24877. doi: 10.1016/j.heliyon.2024.e24877. eCollection 2024 Jan 30.

Authors

Zhi Yang^{1

2}, Liang Sun^{1

2}, Haibin Chen^{1

2}, Caixing Sun^{1

2}, Liang Xia^{1

2}

Affiliations

¹ Department of Neurosurgery, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, China.
² Postgraduate Training Base Alliance of Wenzhou Medical University, WenZhou, 325035, Zhejiang province, China.

Abstract

Diffuse midline glioma with H3K27 M alteration is a primary malignant tumor located along the linear structure of the brain, predominantly manifesting in children and adolescents. The mortality rate is exceptionally high, with a mere 1 % 5-year survival rate for newly diagnosed patients. Beyond conventional surgery, radiotherapy, and chemotherapy, novel approaches are imperative to enhance patient prognosis. This article comprehensively reviews current innovative treatment modalities and provides updates on the latest research advancements in preclinical studies and clinical trials focusing on H3K27M-altered diffuse midline glioma. The goal is to contribute positively to clinical treatment strategies.

Keywords: DIPG; H3K27 M alteration DMG; H3K27 M mutant DMG; Research progress; Therapy.

Publication types

Review